Section
The International Xenotransplantation Association (IXA) 2025 position paper offers evidence-based recommendations for initial clinical trials of genetically engineered porcine kidney transplants for end-stage renal disease, focusing on dono
This article reviews recent studies on EBV transmission in pediatric kidney transplants, highlighting risk factors, monitoring strategies, and implications for reducing posttransplant lymphoproliferative disorder (PTLD).
The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis managem
This post hoc analysis of the ADVOCATE trial demonstrates that avacopan is effective and safe for treating ANCA-associated vasculitis in patients aged 65 and older, achieving sustained remission with reduced glucocorticoid exposure and toxi
Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glu
A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.
This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly
Kidney function influences certain Alzheimer’s disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD
This study demonstrates that triglyceride-glucose-related indices combined with obesity measures significantly predict cardiovascular outcomes and mortality in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3, offering i
This study demonstrates that insulin resistance indices, particularly TyG-WC, TyG-WHtR, and METS-IR, robustly predict the risk and progression of cardio-renal-metabolic multimorbidity, with inflammation and kidney function mediating these a
This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
An updated meta-analysis of 23 RCTs reveals that physical activity improves cardiorespiratory fitness and HDL cholesterol in adult kidney transplant recipients, suggesting important cardiovascular benefits despite current study limitations.
Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.
A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
This analysis reveals that standard initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI) offers greater quality-adjusted life years (QALYs) at an acceptable increased cost, suggesti
A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.
Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall